- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04466345
Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder
September 19, 2023 updated by: University Health Network, Toronto
Adjunctive Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder: a Randomized, Double-Blind, Placebo-Controlled Study
This study will examine whether semaglutide may improve cognitive function in individuals with major depressive disorder (MDD).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a 16-week, placebo-controlled, randomized, double-blind, clinical trial, involving 60 overweight individuals with MDD and pre-treatment cognitive dysfunction.
Study participants will receive one of the following study interventions in addition to 'standard of care' treatment: once-daily semaglutide, initiated at 3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks; or matching placebo.
Participants will be assessed to examine the effect of semaglutide on their cognitive function.
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rodrigo B. Mansur, MD, PhD
- Phone Number: 416 603 5106
- Email: rodrigo.mansur@uhn.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 2S8
- Recruiting
- Toronto Western Hospital
-
Contact:
- Joshua Di Vincenzo
- Email: joshua.divincenzo@uhnresearch.ca
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Informed consent before study-related activity
- Individuals between the ages of 18 and 60 who meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for MDD
- Overweight (i.e. BMI ≥ 25 kg/m2)
- Below-average (i.e. >1 SD below norm) performance in the Trail Making Test-B (TMTB)
Exclusion Criteria:
- Current, or in the past 4 weeks, treatment with other oral hypoglycemic agents and/or insulin
- Diagnosis of possible or probable Alzheimer's Disease, Mild Cognitive Impairment, or any other dementia
- History of neurological disorder, or evidence of neurologic or other physical illness that could produce cognitive deterioration
- Severe mood episode, defined as a Hamilton Depression Rating Scale (HAMD-17) score of >23
- Actively suicidal or evaluated as being a suicide risk (operationalized as a score of ≥3 on HAMD-17 suicide item and/or by clinical assessment).
- Substance use disorder within 3 months before screening or a positive baseline toxicology screen
- DSM-5 diagnosis of obsessive compulsive disorder, posttraumatic stress disorder (current or within the last year), or borderline personality disorder as assessed by a study investigator
- Presence of absolute or relative contraindication to semaglutide (e.g. hypersensitivity to semaglutide, hepatic impairment, renal impairment with chronic kidney disease stage 3 and above, personal or familial history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2)
- History of diabetic retinopathy
- History of pancreatitis or pancreatic cancer
- Presence of clinically unstable general medical illness
- Pregnancy or breastfeeding women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Semaglutide
Participants receive semaglutide once daily orally, initiated at 3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks (i.e., duration of 16 weeks in total).
|
3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks
|
Placebo Comparator: Placebo
Participants receive matching semaglutide placebo capsules once daily (duration of 16 weeks).
|
Semaglutide placebo capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Executive Function Composite Score
Time Frame: 16 Weeks
|
The primary outcome will be an executive function composite score.
This score will be comprised of the Digit Symbol Substitution Test (DSST - number of symbols), the Stroop test (time to completion in the congruent and incongruent conditions), and the Spatial n-back (reaction times and accuracy in four conditions,1-back, 2-back, 3-back, and 4-back).
|
16 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sheehan Disability Scale (SDS)
Time Frame: 12 Weeks
|
SDS is used to assess functional impairment in work/school, social life, and family life.
|
12 Weeks
|
Digit Symbol Substitution Test (DSST)
Time Frame: 16 Weeks
|
DSST is a neurocognitive test designed to assess motor speed and concentration.
|
16 Weeks
|
Rey Auditory Verbal Learning Test (RAVLT)
Time Frame: 16 Weeks
|
RAVLT is a neurocognitive test designed to assess verbal learning and memory.
|
16 Weeks
|
Stroop Test
Time Frame: 16 Weeks
|
The Stroop Test is a neurocognitive test designed to assess the ability to inhibit cognitive interference.
|
16 Weeks
|
Trail Making Test A (TMTA)
Time Frame: 16 Weeks
|
TMTA is a neurocognitive test designed to assess visual scanning and attention.
|
16 Weeks
|
Perceived Deficits Questionnaire (PDQ)
Time Frame: 16 Weeks
|
PDQ is used to assess subjective cognitive dysfunction.
|
16 Weeks
|
36-Item Short Form Health Survey (SF-36)
Time Frame: 16 Weeks
|
SF-36 is used to assess quality of life.
|
16 Weeks
|
Endicott Workplace Productivity Scale (EWPS)
Time Frame: 16 Weeks
|
EWPS is used to assess workplace productivity.
|
16 Weeks
|
Height
Time Frame: 16 Weeks
|
Unit: cm
|
16 Weeks
|
Weight
Time Frame: 16 Weeks
|
Unit: kg
|
16 Weeks
|
fasting glucose - Blood laboratorial marker
Time Frame: 16 Weeks
|
16 Weeks
|
|
Diet History Questionnaire III (DHQ)
Time Frame: 16 Weeks
|
DHQ is a freely available questionnaire used to assess dietary intake (https://epi.grants.cancer.gov/dhq3/).
|
16 Weeks
|
Physical Activity Questionnaire (IPAQ)
Time Frame: 16 Weeks
|
IPAQ is used to assess physical activity.
|
16 Weeks
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: 16 Weeks
|
PSQI is used to assess sleep quality.
|
16 Weeks
|
Trail Making Test B (TMTB)
Time Frame: 16 Weeks
|
TMTB is a neurocognitive test designed to assess attention and concentration.
|
16 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Rodrigo B. Mansur, MD, PhD, University Health Network, Toronto
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 6, 2021
Primary Completion (Estimated)
October 5, 2024
Study Completion (Estimated)
October 5, 2024
Study Registration Dates
First Submitted
June 8, 2020
First Submitted That Met QC Criteria
July 9, 2020
First Posted (Actual)
July 10, 2020
Study Record Updates
Last Update Posted (Actual)
September 21, 2023
Last Update Submitted That Met QC Criteria
September 19, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-6283
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Semaglutide
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
Novo Nordisk A/SCompletedType 2 Diabetes | Healthy VolunteersUnited States, Canada
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States, Italy, Spain, Canada, Hungary
-
Novo Nordisk A/SCompletedObesity | OverweightJapan, Korea, Republic of
-
Novo Nordisk A/SCompletedOverweight or Obesity | Metabolism and Nutrition DisorderUnited States, India, Mexico, Russian Federation, United Kingdom, Canada, Denmark, Finland, Belgium, Japan, Taiwan, France, Poland, Germany, Bulgaria, Argentina, Puerto Rico
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States, India, Japan, Russian Federation, United Kingdom, Canada, Spain, South Africa, Germany, Greece, United Arab Emirates, Argentina, Puerto Rico
-
Novo Nordisk A/SCompletedObesityUnited States, Israel, United Kingdom, Denmark, Germany, Netherlands, Canada, Argentina, Czechia, Hungary, Poland, Spain, Australia
-
Novo Nordisk A/SCompletedObesity | Diabetes Mellitus, Type 2 | OverweightKorea, Republic of, Hong Kong, Brazil, China
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States
-
Novo Nordisk A/SRecruiting